Kalon Stake Gives Fujifilm Ebola Vaccine Capacity
This article was originally published in PharmAsia News
Executive Summary
A Fujifilm Holdings Corp. subsidiary is to acquire a major stake in a private U.S. contract vaccine manufacturing firm, expanding the Japanese group's interests in the growing biologics production field and providing it with new capabilities for Ebola vaccines if needed.
You may also be interested in...
How BARDA Locked Up COVID-19 Vaccine Manufacturing Capacity For Operation Warp Speed
US agency avoided procurement delays with sole-source awards to two medical countermeasures venture partners worth nearly $900m.
Fujifilm Promises A Shake-Up Of Regenerative Medicines Market
Fujifilm has successfully transformed its business strategy by expanding away from traditional photographic film and toward new priority business fields – significantly in regenerative medicine. Identifying health care as a key growth area, Fujifilm targets the role of being a comprehensive provider in the fields of prevention, diagnosis and treatment.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.